3 completed, 1 active not recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Gesynta Pharma AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis Vipoglanstat, Placebo - Endometriosis | Phase 2 | Active not recruiting | Gesynta Pharma AB | 213 | 2025-10-15 | 2026-10-20 |
| A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis GS-248, Placebo - Systemic Sclerosis | Phase 2 | Completed | Gesynta Pharma AB | 94 | 2020-12-29 | 2024-08-09 |
| A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248 Formulation A GS-248, Formulation B GS-248 - Pharmacokinetic | Phase 1 | Completed | Gesynta Pharma AB | 14 | 2020-03-31 | 2021-08-31 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248 GS-248, Placebo - Healthy | Phase 1 | Completed | Gesynta Pharma AB | 72 | 2019-07-03 | 2023-10-11 |
Dysmenorrhea (1) · Endometriosis (1) · Pelvic Pain (1) · Scleroderma, Systemic (1)
Poland (2) · Sweden (2) · United Kingdom (2) · Belgium (1) · Bulgaria (1) · Czechia (1) · Hungary (1) · Italy (1) · Netherlands (1) · Romania (1)
Charlotte Edenius (1) · Helena Litorp, MD, PhD (1)
2025 (1)